AnaCardio raises €62.5 million in Series B co-led by Novo Holdings, Sound Bioventures joins investors

By Public Technologies
  • AnaCardio closed a EUR 62.5 million Series B round to fund late-stage development of its lead heart failure drug, AC01.
  • Sound Bioventures participated alongside co-leads Novo Holdings and the Ljungström family office, with Helsinn also investing.
  • Proceeds earmarked for the GOAL-HF2 Phase 2b trial, targeting Phase 3 readiness for AC01 by 2028.
  • AC01 is a first-in-class oral ghrelin receptor agonist aimed at improving cardiac contractility in advanced HFrEF without conventional inotrope safety risks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sound Bioventures Management AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.